CL2017003112A1 - Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo. - Google Patents

Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.

Info

Publication number
CL2017003112A1
CL2017003112A1 CL2017003112A CL2017003112A CL2017003112A1 CL 2017003112 A1 CL2017003112 A1 CL 2017003112A1 CL 2017003112 A CL2017003112 A CL 2017003112A CL 2017003112 A CL2017003112 A CL 2017003112A CL 2017003112 A1 CL2017003112 A1 CL 2017003112A1
Authority
CL
Chile
Prior art keywords
azetidin
acetonitrile
processes
preparation
ethylsulfonyl
Prior art date
Application number
CL2017003112A
Other languages
English (en)
Inventor
Michael Edward Kobierski
Michael E Kopach
Joseph R Martinelli
David Lee Varie
Thomas Michael Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56204068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2017003112A1 publication Critical patent/CL2017003112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>PROCESOS E INTERMEDIARIOS PARA LA PREPARACIÓN DE {1-(ETILSULFONIL)-3-[4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL]AZETIDIN-3-IL}ACETONITRILO.</p>
CL2017003112A 2015-06-19 2017-12-05 Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo. CL2017003112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562182040P 2015-06-19 2015-06-19

Publications (1)

Publication Number Publication Date
CL2017003112A1 true CL2017003112A1 (es) 2018-06-01

Family

ID=56204068

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003112A CL2017003112A1 (es) 2015-06-19 2017-12-05 Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.

Country Status (26)

Country Link
US (2) US20180134713A1 (es)
EP (1) EP3310781A1 (es)
JP (1) JP2018519280A (es)
KR (1) KR20180008637A (es)
CN (1) CN107660206A (es)
AR (1) AR104918A1 (es)
AU (1) AU2016280815A1 (es)
BR (1) BR112017024613A2 (es)
CA (1) CA2984627A1 (es)
CL (1) CL2017003112A1 (es)
CO (1) CO2017013226A2 (es)
CR (1) CR20170533A (es)
DO (1) DOP2017000300A (es)
EA (1) EA201792308A1 (es)
EC (1) ECSP17083426A (es)
HK (1) HK1248699A1 (es)
IL (1) IL255386A0 (es)
MA (1) MA45901A (es)
MX (1) MX2017015837A (es)
NZ (1) NZ736999A (es)
PE (1) PE20180504A1 (es)
PH (1) PH12017502360A1 (es)
SV (1) SV2017005586A (es)
TN (1) TN2017000530A1 (es)
TW (1) TWI622591B (es)
WO (1) WO2016205487A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
WO2018133875A1 (zh) 2017-01-23 2018-07-26 上海长森药业有限公司 Jak酶抑制剂及其制备方法和用途
CN106946917B (zh) * 2017-03-20 2019-06-11 杭州科巢生物科技有限公司 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
CN107739328B (zh) * 2017-11-22 2020-03-20 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体1的制备方法
CN108129482A (zh) * 2017-12-13 2018-06-08 江苏中邦制药有限公司 一种巴瑞替尼的制备方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
AR116592A1 (es) 2018-10-17 2021-05-26 Lilly Co Eli Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
EP3958968A1 (en) 2019-04-24 2022-03-02 Elanco Us Inc. A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor
KR20240027044A (ko) 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821374A (en) * 1995-11-21 1998-10-13 Hoffmann-La Roche Inc. Process for the oxidation of alcohols
ES2602577T3 (es) * 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
NZ603446A (en) * 2010-04-14 2014-05-30 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
CN102557901B (zh) * 2010-12-15 2014-06-11 上海医药工业研究院 6-氯己醛的制备方法
CN105189509B (zh) * 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
CN105541891B (zh) * 2016-02-04 2017-11-28 东南大学 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法

Also Published As

Publication number Publication date
HK1248699A1 (zh) 2018-10-19
TN2017000530A1 (en) 2019-04-12
AR104918A1 (es) 2017-08-23
TW201712015A (zh) 2017-04-01
AU2016280815A1 (en) 2017-11-23
IL255386A0 (en) 2017-12-31
CA2984627A1 (en) 2016-12-22
MA45901A (fr) 2019-06-19
BR112017024613A2 (pt) 2018-07-31
TWI622591B (zh) 2018-05-01
MX2017015837A (es) 2018-04-10
SV2017005586A (es) 2018-04-24
EA201792308A1 (ru) 2018-05-31
US20180134713A1 (en) 2018-05-17
NZ736999A (en) 2019-05-31
PH12017502360A1 (en) 2018-06-25
WO2016205487A1 (en) 2016-12-22
CR20170533A (es) 2018-01-25
CO2017013226A2 (es) 2018-03-28
US20190062337A1 (en) 2019-02-28
KR20180008637A (ko) 2018-01-24
DOP2017000300A (es) 2018-01-31
ECSP17083426A (es) 2018-02-28
JP2018519280A (ja) 2018-07-19
EP3310781A1 (en) 2018-04-25
PE20180504A1 (es) 2018-03-09
CN107660206A (zh) 2018-02-02

Similar Documents

Publication Publication Date Title
CL2017003112A1 (es) Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu&#39;inhibiteurs de la kinase ret
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EP3138842A4 (en) Polyfluorinated compounds acting as bruton&#39;s tyrosine kinase inhibitors
EP3405192A4 (en) INHIBITORS OF BRUTON TYROSINE KINASE
EP3159340A4 (en) New bruton&#39;s tyrosine kinase inhibitor
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3270926A4 (en) Triazolyl pyrimidinone compounds as pde2 inhibitors
ZA201902370B (en) Novel paratransgenic system for the biocontrol of disease-transmitting mosquitos
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu&#39;inhibiteurs de pde2
EP3475797A4 (en) SEARCH SYSTEM WITH RESULTS FEEDBACK
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
HK1232076A1 (zh) 用於取代的 -芐基- 異噁唑- -基甲基 -吡唑- -基 咪唑烷- -二酮的合成的改進方法
CL2016002256A1 (es) Un proceso mejorado para la preparación de exametazima
EA201791596A1 (ru) Пиразоловые соединения
EP3727387A4 (en) PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
MA46463A (fr) Composés de pyrazolo[1,5-a]pyridine substitués en tant qu&#39;inhibiteurs de la kinase ret
UA114708U (uk) Тяговий привід електробуса
SE1500382A1 (sv) Passive Wireless Repeater
TWD173725S (zh) 眼鏡（二）
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds
TWD173907S (zh) 眼鏡
TWD171971S (zh) 眼鏡